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Abstract
Objective: A growing body of evidence suggests that increased blood–brain
barrier (BBB) permeability can contribute to the development of seizures. The
protease tissue plasminogen activator (tPA) has been shown to promote BBB
permeability and susceptibility to seizures. In this study, we examined the path-
way regulated by tPA in seizures. Methods: An experimental model of kainate-
induced seizures was used in genetically modified mice, including mice deficient
in tPA (tPA/), its inhibitor neuroserpin (Nsp/), or both (Nsp:tPA/), and
in mice conditionally deficient in the platelet-derived growth factor receptor
alpha (PDGFRa). Results: Compared to wild-type (WT) mice, Nsp/ mice
have significantly reduced latency to seizure onset and generalization; whereas
tPA/ mice have the opposite phenotype, as do Nsp:tPA/ mice. Further-
more, interventions that maintain BBB integrity delay seizure propagation,
whereas osmotic disruption of the BBB in seizure-resistant tPA/ mice dra-
matically reduces the time to seizure onset and accelerates seizure progression.
The phenotypic differences in seizure progression between WT, tPA/, and
Nsp/ mice are also observed in electroencephalogram recordings in vivo, but
absent in ex vivo electrophysiological recordings where regulation of the BBB is
no longer necessary to maintain the extracellular environment. Finally, we dem-
onstrate that these effects on seizure progression are mediated through signaling
by PDGFRa on perivascular astrocytes. Interpretation: Together, these data
identify a specific molecular pathway involving tPA-mediated PDGFRa signal-
ing in perivascular astrocytes that regulates seizure progression through control
of the BBB. Inhibition of PDGFRa signaling and maintenance of BBB integrity
might therefore offer a novel clinical approach for managing seizures.
Introduction
The serine protease tissue-type plasminogen activator
(tPA) is primarily known for its thrombolytic activity;
however, within the central nervous system (CNS) tPA is
reported to have pleiotropic effects, regulating events such
as neuronal plasticity, neurovascular coupling, and neuro-
vascular barrier control (reviewed in 1–3). In vitro studies
have demonstrated that tPA activity can be regulated by
neuroserpin,4,5 a member of the serine protease inhibitor
(serpin) family4,6 that is primarily expressed in the brain.4,7
In humans, mutations in the neuroserpin gene have
been linked to epilepsy8,9 and dementia,10,11 and it is
thought that this is due to neurotoxic effects of neuroser-
pin inclusion bodies.11 However, it has been suggested
that the epilepsy phenotype might actually be caused by
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the loss of regulation of tPA activity,12 but so far there is
no direct in vivo evidence linking neuroserpin and tPA in
the brain. The hypothesis that unregulated tPA activity
contributes to epilepsy is supported by work in
rodents.13–15 These studies showed that tPA expression is
increased early after seizures13 and that tPA deficiency
leads to a higher threshold for seizures,14,15 whereas neu-
ronal overexpression leads to a lower seizure threshold.16
In addition, tPA and neuroserpin are rapidly released
from neurons in response to neuronal depolarization.17,18
The relationship between tPA and seizures in humans is
less well understood, but a recent study described a posi-
tive correlation between increased serum tPA levels and
epilepsy severity in children with idiopathic and intracta-
ble epilepsies.19
The mechanism by which tPA affects seizures is not
known. It is possible that tPA acts on neuronal cells
directly to affect neuronal excitability and survival,20,21 or
indirectly by altering cerebrovascular permeability.22,23
We have previously demonstrated an effect of tPA on
blood–brain barrier (BBB) integrity in stroke,22 which is
mediated through cleavage of platelet-derived growth fac-
tor-CC (PDGF-CC)24 and activation of the PDGF recep-
tor alpha (PDGFRa) on perivascular astrocytes.25
However, it is not known whether increases in tPA activ-
ity during seizure leads to loss of BBB control caused by
enhanced PDGF signaling in the neurovascular unit, or if
this affects seizure severity. While it is well-established
that impaired integrity of the BBB is a feature of seizures,
it is debated whether BBB dysfunction is just a conse-
quence of seizure activity or a contributor to seizure pro-
gression (reviewed in 26). The therapeutic potential of
restoring BBB function has therefore been largely over-
looked (reviewed in 27,28). However, as 30% of individu-
als with seizures fail to respond to existing treatments29
recent studies have begun to consider the cerebrovascula-
ture as a potential avenue for therapeutic interven-
tion.27,30–32
In this study, we demonstrate that neuroserpin and
tPA form a regulatory circuit in the murine CNS that
influences seizure progression via tPA-mediated PDGFRa
signaling and control of the BBB. These findings offer
novel targets for anticonvulsant therapy and contribute to
our understanding of the relationship between BBB dysre-
gulation and seizures.
Materials and Methods
Animal strains
Age- and gender-matched tPA (tPA/), neuroserpin
(Nsp/), plasminogen activator inhibitor 1 (PAI-1)
(PAI-1/), and double (Nsp:tPA/) deficient mice
back-crossed at least 10 generations into C57BL/6J and
their wild-type C57BL/6J (WT) controls were used. In
addition, age- and gender-matched conditional PDGFRa-
deficient mice (GFAP-Cre+;Rafl/fl) and littermate controls
(GFAP-Cre;Rafl/fl, GFAP-Cre;Rawt/wt and GFAP-Cre+:
Rawt/wt) were used. All animal experiments were approved
by the local committee for animal experiments at the
University of Michigan, USA and the studies were con-
ducted in accordance with the United States Public
Health Service’s Policy on Humane Care and Use of Lab-
oratory Animals.
Murine model of seizure and EB analysis
The animals were anesthetized with chloral hydrate
(450 mg/kg, Sigma-Aldrich, St. Louis, MO, USA, intraperi-
toneal) and placed in a digital stereotactic frame. 0.5 lL of
16 mmol/L kainic acid (KA, Sigma-Aldrich) diluted in lac-
tated Ringer’s solution was injected unilaterally using a 33G
needle and Hamilton syringe into the basolateral amygdala;
bregma, –1.6 mm; medial-lateral, 2.5 mm; dorso-ventral,
4.5 mm. The injection needle was removed after 4 min
and the animals were observed for 240 min. Behavioral sei-
zures were scored by a blinded investigator as follows:
onset, myoclonic jerks involving the whisker pads; and gen-
eralization, bilateral myoclonic activity. For analysis of
cerebrovascular permeability after KA injection, mice were
injected with 100 lL of 4% Evans blue (EB) (intravenous,
Sigma-Aldrich) in lactated Ringer’s solution 1 h before the
animals were sacrificed by transcardial perfusion with
phosphate-buffered saline (PBS) for 8 min. The brains
were removed and separated into hemispheres ipsilateral
and contralateral to the KA injection. Each hemisphere was
then homogenized in N,N-dimethylformamide (Sigma-
Aldrich) and centrifuged for 45 min at 25,000 g. The su-
pernatants were collected, absorbance determined and EB
extravasation in each hemisphere quantified from the for-
mula: (A620 nm  ((A500 nm + A740 nm)/2))/mg wet
weight.22
Hippocampal local field potential recording
For electroencephalogram (EEG) analysis mice were anes-
thetized with 2% isofluorane. Body temperature was
maintained at 37°C by a temperature-controlled feedback
system. An intraperitoneal catheter was implanted for
administration of chloral hydrate. Mice were placed in a
stereotactic frame and the skull prepared for electrode
placement. Anesthesia was transitioned to chloral hydrate
(450 mg/kg). A monopolar electrode was placed in the
CA1 region of the hippocampus contralateral to the
kainate injection site and a reference electrode was placed
in the cerebellum. With this monopolar recording
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arrangement, the EEG signal primarily reflects neuronal
activity within the hippocampal tissue (hippocampal
seizure activity). EEG activity was recorded using a Bi-
opac 100B amplifier and a Biopac MP100 Data Acquisi-
tion System (Biopac Systems, Goleta, CA, USA). For EEG
analysis, Acknowledge 3.9.1.6 software was used. After
recording baseline EEG activity for 15 min, KA was
injected into the left amygdala as above. EEG activity was
recorded continuously for a minimum of 2 h post injec-
tion. Coordinates for electrode placement (relative to
bregma) were as follows: Contralateral hippocampus: AP:
1.94 mm, ML: 1.0 mm, Depth: 1.5 mm. Cerebellum
reference electrode: AP: 6.0 mm ML: 1.0 mm, Depth:
1.0 mm. For EEG analysis, the average time to sustained
ictal activity was measured by two independent investiga-
tors blinded to study group. For each animal, the ampli-
tude of normal baseline activity was determined as
recurrent bursting of at least three bursts for any given
minute of baseline. A threshold of two times the baseline
amplitude was set and the number of peaks above this
threshold was plotted. The inflection point of this plot
was considered the onset of high amplitude electrical
activity. Ictal activity was confirmed at these time points
by the presence of continuous ictal spiking. If at the onset
of increased electrical activity sustained ictal activity was
not confirmed the first point of continuous spiking above
threshold was taken.
Ex vivo synchronous activity was assessed using a no
Mg2+/high K+ model.33 Hippocampal slices were pre-
pared and extracellular field potential recording methods
were used similar to that previously described.34,35
Briefly, coronal brain slices (350 lm) were cut on a vi-
bratome under ice-cold (<1°C) oxygenated sucrose-based
cutting solution containing the following (in mmol/L):
2.8 KCl, 1.25 MgCl2, 1.0 MgSO4, 1.25 NaH2PO4, 1.25
CaCl2, 206 sucrose, 26 NaHCO3, 10 D-glucose, 0.40
ascorbic acid. Slices were transferred to a holding cham-
ber filled with artificial cerebrospinal fluid (aCSF) con-
taining the following (in mmol/L): 124 NaCl, 2.8 KCl, 1
MgSO4, 1.25 NaH2PO4, 2.5 CaCl2, 26 NaHCO3, 10 D-
glucose, 0.40 ascorbic acid at room temperature and
remained there for at least 1 h before being individually
transferred to a submersion chamber and continuously
perfused (~1.5 mL/min) with oxygenated aCSF heated to
31°C. Extracellular field potential recordings were made
using glass-pipettes filled with aCSF (tip resistances
~1 MO), placed in stratum oriens of region CA3 just
adjacent to the cell body layer. Spontaneous seizure
activity was induced by exchanging the normal aCSF
perfusion with aCSF which contained 0 mmol/L Mg2+
and elevated (10 mmol/L) K+. The latency from the
time of exchange until the first spontaneous high-fre-
quency burst was documented.
Imatinib treatment and mannitol analysis
To block PDGFRa activation, mice were treated with the
tyrosine kinase inhibitor imatinib (200 mg/kg, oral
gavage) three times (morning-night-morning) before KA
injection. Lactated Ringer’s solution was used as vehicle
control. To temporarily induce opening of the BBB, man-
nitol (Sigma-Aldrich) 100 lL of a 1 mol/L solution in
Lactated Ringer’s was infused through the internal carotid
artery 30 min after KA injection. Saline-treated animals
were used as controls. Seizure behavior for both the
imatinib and mannitol experiments was scored as
described above. To demonstrate mannitol-induced open-
ing of the BBB, mannitol was administered to animals
not undergoing craniotomy and immediately followed by
intravenous injection of EB. Cerebrovascular permeability
analysis was carried out as described above.
Immunostaining and confocal microscopy
For immunofluorescence, frozen sections (14 lm) or vi-
bratome sections (50 lm) were used and antigen retrieval
was performed in retrieval solution (S1700; DAKO,
Glostrup, Denmark) by boiling. The sections were per-
meabilized in 0.5% TritonX-100 and nonspecific binding
blocked using TNB blocking buffer (NEL700A001KT, Per-
kin Elmer, Waltham, MA, USA) or 1% Bovine Serum
Albumin (BSA) in 0.5% TritonX-100/PBS. The sections
were incubated with primary antibodies in blocking solu-
tion overnight at 4°C followed by incubation with fluo-
rescent-conjugated secondary antibodies 45 min, room
temperature (RT). The specific primary antibodies used
were as follows: tPA (12 lg/mL, rabbit HTMTPA and
goat SHTMTPA, Molecular Innovations, Novi, MI, USA),
neuroserpin (15 lg/mL, rabbit HTmNs; Lawrence Lab),
Podocalyxin (1:200, AF1556; R&D systems, Minneapolis,
MN, USA), CD31 (rat anti PECAM, 1:50, 553370; BD
Biosciences, Franklin Lakes, NJ, USA), somatostatin (rat
anti SST, 1:200, 8330-0009; AbD Serotec, Oxford, UK),
VIP (Guinea Pig anti VIP, 1:200, S-3048; Bachem, Buben-
dorf, Switzerland), PDGFRa (rabbit anti PDGFRa, 1:100,
#3164; Cell Signaling Technology, Denvers, MA, USA),
glial fibrillary acidic protein (rat anti GFAP, 1:200,
13-0300; Life Technologies, Stockholm, Sweden), and
a-smooth muscle actin-Cy3 (mouse anti ASMA-Cy3,
1:300, C6198; Sigma-Aldrich). To visualize the vessels
with Lycopersicon esculentum (tomato) lectin (# B-1175;
Vector Laboratories, Burlingame, CA, USA), biotinylated-
lectin was dialysed against PBS overnight, and injected via
the tail vein of anesthetized mice (100 lL of 0.7 mg/mL).
After 5 min the mice were perfusion fixed, brains
dissected, sectioned by vibratome and stained with fluo-
rescent-conjugated streptavidin. DAPI (40,6-diamidino-2-
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phenylindole, dihydrochloride, 0.2 lg/mL) was included
in the last PBS wash. The sections were mounted using
ProLong Gold Antifade reagent (P36930; Life Technolo-
gies). Brain sections from tPA/ and Nsp/ mice were
used for antibody control and demonstrated that both
antibodies were specific for their respective antigen and
that tPA appeared to be normally expressed in the brains
of Nsp/ mice and vice versa. All images were acquired
in RT with a Zeiss LSM510 alternatively LSM700 confocal
microscope and the ZEN 2009 software (Carl Zeiss, Ober-
kochen, Germany). The images are representative of the
respective stainings and were processed and analyzed
using Volocity 3D image analysis software (PerkinElmer)
and Photoshop CS5 (Adobe, San Jose, CA, USA). Bright-
ness and contrast settings were changed to generate final
image and were applied equally to entire image.
Statistical analysis
The data are presented as Kaplan–Meier plots in order to
account for mice that did not generalize during the
240 min experimental period, or as mean  SEM. Assis-
tance with statistical analysis was obtained from the Uni-
versity of Michigan Center for Statistical Consultation
and was performed using GraphPad Prism 6 statistical
software (GraphPad Software, La Jolla, CA, USA). Signifi-
cant outliers were identified and excluded based on
Grubb’s test with significance level alpha set to 0.05.
Analysis for significance was performed as indicated in
the figure legends and is summarized in Table S1. All
experiments were repeated at least two independent times
and n indicates the number of individual mice used in
the study. P values less than 0.05 were considered statisti-
cally significant and are indicated in the figures by an
asterisk.
Results
Neuroserpin and tPA form a regulatory
circuit in the murine CNS
The main inhibitor of tPA activity in blood is the serpin
PAI-1; however, based on both in vitro studies and expres-
sion analysis it has been hypothesized that neuroserpin is
the primary inhibitor of tPA activity in the CNS.4,5,36 To
study the role and putative in vivo link between neuroser-
pin and tPA in seizure onset and progression we used a
murine model of seizure where the chemo-convulsant KA
was injected into the basolateral nucleus of the amyg-
dala.15 This brain structure is part of the limbic system
but distant from the hippocampus, thus this model
permits the investigation of seizure activity within the
limbic system without direct injection of excitotoxins into
the hippocampus proper. The behavioral response to
injection of KA into the amygdala is characterized by uni-
lateral myoclonic contractions of the face (onset, Fig. 1A),
which ultimately spread to full generalization involving
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Figure 1. Neuroserpin/tPA regulate severity of KA-induced seizures in
mice. Seizures were induced with KA and convulsive behavior/severity
was scored as: (A) Onset, seizures affecting one side of the face or
neck; (B) Generalization, bilateral seizure activity involving four limbs;
and (C) Survival. All data are presented as Kaplan–Meier plots in wild-
type mice (WT, n = 24); neuroserpin-deficient mice (Nsp/, n = 15);
PAI-1-deficient mice (PAI-1/, n = 16); tPA-deficient mice (tPA/,
n = 14); neuroserpin and tPA double-deficient mice (Nsp:tPA/,
n = 10). Median times (t) or survival proportions at 240 min (%) are
indicated in the figure. The data are from 2 to 7 independent
experiments. Statistical significance was determined by log-rank
(Mantel–Cox) test and *P < 0.05; **P < 0.01; ***P < 0.001;
ns = nonsignificant relative to controls. tPA, tissue plasminogen
activator; KA, kainic acid; PAI, plasminogen activator inhibitor 1.
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all four limbs (generalization, Fig. 1B).15 Scoring of these
behavioral manifestations during the first 4 h following
KA injection in C57BL/6J WT (n = 24), neuroserpin defi-
cient (Nsp/, n = 15), PAI-1 deficient (PAI-1/,
n = 16), tPA deficient (tPA/, n = 14), and double neu-
roserpin/tPA deficient (Nsp:tPA/, n = 10) mice revealed
that Nsp/ and tPA/ mice display opposite seizure
phenotypes (Fig. 1). We found that Nsp/ mice experi-
enced very severe seizures with significantly decreased
latency to onset (P < 0.05) (Fig. 1A) and generalization
compared to WT controls (P < 0.01) (Fig. 1B). In con-
trast, we found that tPA/ mice showed a significantly
delayed latency to onset and generalization compared to
WT controls (onset, P < 0.05; generalization, P < 0.001)
(Fig. 1A and B). This latter result is consistent with previ-
ously published data.14,15 We also found that seizure pro-
gression in PAI-1/ mice phenocopied WT controls
(onset, P = 0.22; generalization, P = 0.60), suggesting that
PAI-1 is not regulating tPA activity in the brain during
seizures (Fig. 1A and B). These findings are supported by
quantitative real-time PCR experiments showing that neu-
roserpin expression is high, whereas PAI-1 expression is
low in both the murine (data not shown) and human
brain.7,37
To investigate if the opposing effects of neuroserpin
and tPA on seizure progression are due to regulation of
tPA activity by neuroserpin, we created mice lacking
expression of both proteins. We reasoned that the pheno-
type of the double-deficient mice (Nsp:tPA/) would
either mimic the severe phenotype of Nsp/ mice, be
intermediate to Nsp/ and tPA/ mice if the effect of
neuroserpin is independent of tPA activity, or phenocopy
the tPA/ mice if neuroserpin acts upstream of tPA, reg-
ulating its activity. Comparing the Nsp:tPA/ mice with
each single-deficient strain revealed that the double-defi-
cient mice phenocopied tPA/ mice (onset, P = 0.47;
generalization P = 0.49) and were largely protected from
seizure progression to generalized seizures (Fig. 1A and
B). In contrast, Nsp:tPA/ mice had a significantly
delayed latency to onset and generalization compared to
Nsp/ mice (onset and generalization, P < 0.001). The
results from the scoring of behavioral manifestations were
confirmed by analysis of survival of the various genotypes
(Fig. 1C). Nsp/ mice showed a significantly shorter
mean time of survival than any of the other genotypes
(P < 0.01 vs. WT) with a survival of only 20% at the 4-h
time point. tPA/ and double-deficient Nsp:tPA/ mice
were protected from seizure-induced death, with both
strains showing a survival of 100% at 4 h after KA injec-
tion. WT and PAI-1/ mice showed similar rates of sur-
vival (about 57%) at the endpoint, which is intermediate
to the Nsp/ mice, and the tPA/ or Nsp:tPA/ mice.
Taken together, the opposing seizure phenotypes observed
in tPA/ and Nsp/ mice, as well as the results with
the Nsp:tPA/ and PAI-1/ mice, indicate that neuro-
serpin is primarily acting as an inhibitor of tPA in the
murine brain during seizure.
Seizure severity correlates with BBB
permeability
As vascular permeability has been shown to be increased
during seizures27,38 and tPA has been shown to regulate
the integrity of the BBB,22 we investigated whether neuro-
serpin and tPA affect seizures through control of vascular
integrity. We first determined whether the integrity of the
BBB was affected in our experimental model of seizure by
measuring EB dye extravasation into the brain paren-
chyma at 2 and 4 h after KA injection in WT mice
(n = 10), at 2 h in Nsp/ mice (n = 11), and at 4 h in
tPA/ mice (n = 7) (Fig. 2A). Our results showed a sig-
nificant, time-dependent increase in EB extravasation in
the hemisphere ipsilateral to the KA injection in WT
mice, demonstrating an increased loss of BBB control
from 2–4 h (P < 0.001). Unlike WT mice, the Nsp/
mice already showed a loss of BBB control at 2 h com-
pared saline-injected controls (P < 0.01), and compared
to WT mice there was a significant increase in EB leakage
in the ipsilateral hemisphere of Nsp/ mice 2 h after KA
injection (P < 0.05). In contrast, the tPA/ mice were
protected from loss of BBB control. Even 4 h after KA
injection they showed only a nonsignificant increase in
EB leakage compared to saline-injected tPA/ mice and
significantly less EB leakage compared to WT mice at 4 h
(P < 0.001) (Fig. 2A) (due to the low survival of the
Nsp/ mice we were not able to measure EB extravasa-
tion at 4 h in these mice). Interestingly, we also found a
significant increase in EB extravasation in the contralat-
eral hemisphere of WT mice at 4 h compared to saline-
injected controls and to KA-injected WT mice at 2 h
(P < 0.001) (Fig. 2B). No significant differences were
detected in baseline EB extravasation between the three
genotypes or between any of the sham operated saline-
injected controls (Table S1). These data indicate that
decreased BBB integrity accompanies the propagation of
abnormal electrical activity as the seizure spreads from
the ipsilateral to the contralateral hemisphere. Together
they confirm that this seizure model is associated with
vascular leakage, similar to what has been reported in sei-
zure patients,27 and that the extent of BBB opening corre-
lates with seizure severity. This is illustrated by the higher
EB values recorded in Nsp/ mice compared to WT con-
trols at 2 h post-KA injection; at which time ~80% of the
Nsp/ mice, but only ~20% of the WT controls, had
progressed into generalized seizures. In contrast, at the
later time point only about half of the tPA/ animals
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had progressed into generalized seizures as compared to
all of their WT controls, which correlated with lower EB
leakage in tPA/ mice.
Neuroserpin and tPA are expressed in
perivascular cells in the murine brain
To investigate the potential association of neuroserpin and
tPA with cerebral vessels we performed immunofluores-
cent staining on WT murine brain tissue sections and
analyzed the expression of neuroserpin and tPA by confo-
cal microscopy. Neuroserpin was detected on the brain
parenchymal side of the cerebral vessels in perivascular
cells with projections that appeared to interact with the
cerebrovascular wall (arrowheads, Fig. 3A). Consistent
with previous publications we found two distinct pools of
tPA expression associated with cerebral vessels in the mur-
ine brain: one pool was found throughout the brain
within vascular endothelial cells (arrowheads, Fig. 3B),39
whereas a second pool was found in close proximity to
arterioles on the brain parenchymal side of the cerebral
vessels (arrows, Fig. 3B).25,40 Costaining analysis of neuro-
serpin (green, arrowheads) and tPA (red, arrows) expres-
sion in the cerebral vasculature revealed that the protease
and its inhibitor were expressed in close proximity to each
other around cerebral vessels, but that they were localized
to different cellular compartments (Fig. 3C).
The size of the perivascular cells expressing neuroser-
pin and tPA, and the localization of neuroserpin to cel-
lular projections innervating the cerebrovascular wall,
suggested that neuroserpin and tPA-positive cells might
be neurons involved in regulation of vascular function.
As GABAergic (gamma-aminobutyric acid) neurons have
been reported to show the highest expression of neuro-
serpin in the human brain,9 and subsets of GABAergic
interneurons have been reported to regulate vascular
responses such as vascular tone,41–43 we next investigated
whether neuroserpin and tPA in the murine brain are
coexpressed with different markers of these cells, includ-
ing somatostatin (SST) and vasoactive intestinal peptide
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Figure 2. KA-induced seizures increase vascular permeability. (A) Changes in vascular permeability were determined by quantitative analysis of
Evans blue (EB) extravasation in the ipsi-lateral hemisphere of KA-injected wild-type mice (WT, n = 10 for the respective time points), neuroserpin-
deficient mice (Nsp/, n = 11), tPA-deficient mice (tPA/, n = 7), and their respective sham-operated saline-injected controls (WT, n = 10–11;
Nsp/, n = 10; tPA/, n = 9). (B) Contralateral EB extravasation in WT mice following KA-injection (n = 10 for the respective time points) and
sham-operated saline-injected controls (n = 10–11). Extravasation was determined at 2 h (WT and Nsp/) and 4 h (WT and tPA/) after KA
injection, and EB was injected 1 h before termination of the experiment. The results are displayed in scatter dot plots as fold change in sham-
operated baseline, and the lines indicate mean  SEM. The data are from 2 to 5 independent experiments. Statistical significance was determined
by one-way ANOVA (multiple comparisons) and *P < 0.05; **P < 0.01; ***P < 0.001; ns = non significant relative to controls. KA, kainic acid;
tPA, tissue plasminogen activator; ANOVA, analysis of variance.
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(VIP). VIP-expressing “vasomotor” interneurons induce
dilation of local microvessels, whereas SST-expressing in-
terneurons induce contraction.41 Our immunostainings
of murine brain sections revealed that neuroserpin is
expressed by perivascular SST-positive cells (Fig. 4A),
whereas tPA is expressed by VIP-positive cells (Fig. 4B).
This is supportive of a role of neuroserpin and tPA in
control of cerebrovascular responses during seizure pro-
gression.
Protection of the BBB delays seizure onset
and progression
Several studies have suggested that BBB disruption can
promote seizures27,30–32 and we have previously shown
that tPA, via PDGFRa-activated signaling in the neuro-
vascular unit, controls BBB integrity.22,25 Therefore, to
investigate whether preservation of barrier integrity dur-
ing seizures contributes to seizure resistance we used both
pharmacologic and genetic strategies to maintain barrier
function by inhibiting tPA-mediated PDGFRa signaling.
We hypothesized that inhibition of tPA-induced PDGFRa
signaling would result in less severe seizures through pro-
tection of BBB integrity. Consistent with our hypothesis
we found that pharmacologic inhibition of PDGFRa sig-
naling with the receptor tyrosine kinase inhibitor imatinib
resulted in a significant delay in both onset (Fig. 5A) and
generalization (Fig. 5B) of KA-induced seizure in both
WT (n = 27) and neuroserpin-deficient mice (Nsp/,
n = 14), but not in tPA-deficient mice (tPA/, n = 10),
as compared to vehicle-treated controls (WT, n = 20;
Nsp/, n = 14; tPA/, n = 14). In WT and Nsp/
mice the median time to onset was about 45–55% slower
following imatinib treatment compared to vehicle controls
(WT, P < 0.001; Nsp/, P < 0.05) and generalization
was about 15–30% slower (WT, P = 0.05; Nsp/,
P < 0.05). In tPA/ mice, which demonstrate marginal
BBB leakage of EB after seizure induction (see Fig. 2A)
and low PDGFRa-activation after experimentally induced
ischemic stroke,25 there was no effect from imatinib on
seizure activity (onset, P = 0.88; generalized, P = 0.98).
Our results imply that maintenance of BBB integrity
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Figure 3. Neuroserpin and tPA are highly expressed in the murine brain. The expression of neuroserpin (Nsp) and tPA in the murine brain was
analyzed by immunofluorescent confocal microscopy. (A and B) Analysis of stained wild-type brain sections showed that neuroserpin (A, green)
was highly expressed in perivascular cells with cellular projections that appeared to innervate the cerebrovascular wall (arrowheads) and that tPA
(B, green) was expressed as two distinct pools associated with the cerebral vessels; one within the endothelial cells (arrowheads) and another on
the abluminal side of the vessels (arrows). Vessels were visualized using the endothelial cell marker podocalyxin (A and B, Podo, red) and the xyz
distribution is shown in (A0 and B0). (C) Costaining of neuroserpin (green, arrowheads) and tPA (red, arrows) revealed that the two are expressed
by different perivascular cells in the wild-type murine brain. Vessels were visualized using the endothelial cell marker CD31 (PECAM, white). Cell
nuclei were visualized with DAPI (blue). The pictures are representative images from stainings on sections from three mice per genotype (n = 3),
and the stainings were repeated three to five independent times per animal. The pictures were captured in the hippocampus. (A and B) The
maximum intensity projection and C the two-dimensional rendering of the three-dimensional reconstruction generated from confocal Z stacks.
Scale bars, 10 lm. tPA, tissue plasminogen activator; DAPI, 40,6-diamidino-2-phenylindole, dihydrochloride.
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delays seizure progression and that imatinib, possibly
through inhibition of tPA-catalyzed PDGFRa signaling in
the neurovascular unit, might offer a novel clinical
approach for treating seizures.
To more precisely identify the molecular target of
imatinib we further investigated the link between tPA-cat-
alyzed activation of PDGFRa signaling in the neurovascu-
lar unit and experimentally induced seizures. Based on
our previous findings that showed PDGFRa to be
expressed on perivascular astrocytes in the neurovascular
unit, we generated astrocyte-specific PDGFRa-deficient
mice. For this, we utilized floxed PDGFRa mice44 and a
transgenic mouse strain expressing Cre recombinase
under the control of the human glial fibrillary acidic pro-
tein promoter (GFAP-Cre).45 Immunofluorescent staining
of WT murine brain tissue sections confirmed expression
of PDGFRa in GFAP-positive perivascular astrocytes in
the neurovascular unit (Fig. 6A) and showed that the
receptor is distributed in the border between the astro-
cytes and the vascular mural cells, here visualized by
ASMA (Fig. 6B). Characterization of the conditional
PDGFRa-deficient strain demonstrated that perivascular
PDGFRa expression was very low in the conditional mice
(Cre+;Rafl/fl) as compared to floxed PDGFRa littermate
controls (Cre;Rafl/fl) (Fig. 7A). Quantification of
PDGFRa expression (n = 3 per genotype) revealed a sig-
nificant reduction (~50% lower) in receptor levels in con-
ditional Cre+;Rafl/fl mice as compared to floxed Cre;Rafl/
fl littermate controls (P < 0.05) (Fig. 7B). Supporting our
data with pharmacologic inhibition of PDGFRa signaling
using imatinib, we found that astrocyte-specific ablation
of PDGFRa in Cre+;Rafl/fl mice (n = 10) significantly
delayed progression into generalized seizures following
KA injection compared to floxed Cre;Rafl/fl controls
(n = 10) (P < 0.05) (Fig. 7C). This delay was not due to
the presence of GFAP-driven Cre recombinase per se as
KA-induced seizure onset and progression in Cre+;Rawt/wt
mice (n = 5) phenocopied WT Cre;Rawt/wt littermate
controls (n = 6) (Fig. 7D). We noted that floxed Cre;
Rafl/fl mice had faster time to onset and generalization
(Fig. 7C) than WT Cre;Rawt/wt mice (Fig. 7D) which is
possibly due to a reduction in PDGFRa expression in
nonperivascular cells in the murine brain of floxed Cre;
Rafl/fl mice (Fig. 7E).44 Together our results suggest that
tPA-catalyzed activation of PDGFRa signaling in perivas-
cular astrocytes play a role in seizure spreading and that
inhibition of this signaling pathway in the astrocytes of
the neurovascular unit reduces seizure severity.
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Figure 4. Neuroserpin and tPA are expressed in perivascular neurons. Perivascular expression of neuroserpin and tPA in the murine brain was
analyzed by immunofluorescent confocal microscopy. (A) Costaining of neuroserpin (Nsp, green) with somatostatin (SST, red) as a marker of
vasoactive inhibitory interneurons shows coexpression of neuroserpin in somatostatin-positive cells (yellow, merged picture and xyz distribution).
The double neuroserpin and somatostatin-positive interneurons often appeared to innervate the vascular wall (arrowheads). Vessels were
visualized using the endothelial cell marker podocalyxin (Podo, white). (B) Costaining of tPA (green) with VIP (red) as a marker of vasoactive
interneurons shows coexpression of tPA in VIP-positive cells (yellow, merged picture and xyz distribution). Vessels were visualized using lectin
(Lectin, white). The pictures are representative images from stainings on sections from three mice per genotype (n = 3). The pictures were
captured in the hippocampus. Cell nuclei were visualized with DAPI (blue). (A and B) The two-dimensional rendering of the three-dimensional
reconstruction generated from confocal Z stacks. Scale bars, 10 lm. tPA, tissue plasminogen activator; VIP, vasoactive intestinal peptide; DAPI,
40,6-diamidino-2-phenylindole, dihydrochloride.
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Osmotic opening of the BBB enhances
seizure onset and progression in tPA/ mice
Although our data imply a correlation between BBB per-
meability and seizures, it is still possible that removing or
inhibiting PDGFRa signaling in perivascular astrocytes
affect seizures in an unanticipated way and that the
opening of the BBB is just a consequence of the seizure
activity. Therefore, to address the relationship between
increased BBB permeability and seizure progression we
used high molarity mannitol, administered through the
internal carotid artery, to induce opening of the BBB.
Mannitol has been shown to cause opening of the BBB
through vasodilation and shrinkage of endothelial cells,
which results in widening of the interendothelial tight
junctions.46 If decreased integrity of the BBB promotes
seizure progression we hypothesized that mannitol treat-
ment would enhance the severity of seizures in otherwise
protected tPA/ mice. Conversely, if the role of tPA in
seizure spreading is mediated in a vascular-independent
manner then mannitol would not affect the protected
phenotype seen in tPA/ mice. For these studies, we first
measured EB leakage into the brain parenchyma to con-
firm that the BBB in tPA/ mice could be manipulated
by mannitol (Fig. 8A). We found significantly increased
EB extravasation in tPA/ animals following mannitol
injection (n = 6) as compared to controls (n = 4)
(P < 0.05, Fig. 8B). Assessment of behavioral seizure
manifestation in tPA/ mice after mannitol-induced
opening of the BBB (n = 8) revealed significantly faster
onset time of seizures (P < 0.05) (Fig. 8C) and faster time
to generalization (P < 0.001) (Fig. 7D) compared to
Ringer’s infused controls (n = 7). This indicates that the
tPA/ mice are not inherently protected from severe sei-
zures and that opening of the BBB enhances seizure pro-
gression. Interestingly, mannitol has been reported to be
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Figure 5. Pharmacologic inhibition of tPA-catalyzed PDGF signaling improves seizure outcome. Pharmacologic inhibition of tPA-induced PDGF
signaling with imatinib and behavioral scoring as described in Figure 1 produced a significant delay in both onset (A) and generalization (B) of
KA-induced seizures in both wild-type (WT, n = 27) and neuroserpin-deficient (Nsp/, n = 14) mice, but not in tPA-deficient mice (tPA/,
n = 10) as compared to vehicle-treated controls (WT, n = 20; Nsp/, n = 14; tPA/, n = 14). Data are presented as Kaplan–Meier plots of
seizure progression and median time (t) is indicated in the figure. In (A and B) results with the individual genotypes are shown in the smaller
plots. The data are from 3 to 5 independent experiments. Statistical significance was determined by log-rank (Mantel-Cox) test. P value is relative
to the respective controls and is indicated in the figure. tPA, tissue plasminogen activator; PDGF, platelet-derived growth factor; KA, kainic acid.
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associated with seizures when administered as a means to
lower intracranial pressure caused by brain edema follow-
ing traumatic brain injury (TBI),47 or when administered
as a way to enhance the entry of chemotherapeutic agents
for treating brain tumors.31 Our results suggest that the
mechanism behind the seizure side effects accompanying
osmotherapy with mannitol might be that decreased BBB
integrity lowers the threshold for neuronal synchronous
activity.
Seizure onset/progression is regulated at
the level of the neurovascular unit
To further investigate the neurovascular role of neuroser-
pin/tPA in seizure progression we carried out electrophysi-
ological experiments. For this, we used in vivo
hippocampal EEG recordings and an ex vivo seizure
model.33 We reasoned that if the differences in seizure
progression observed between the tPA/ and Nsp/
mice were driven by differences in BBB integrity, then
these phenotypic differences in seizure progression would
be absent in an ex vivo preparation where the BBB plays
no role in regulation of the parenchymal extracellular
environment. Alternatively, if the phenotypic differences
were independent of BBB integrity then these differences
should be maintained in ex vivo electrophysiological exper-
iments. Consistent with the behavioral seizure scoring
data, in vivo EEG recordings confirmed an increased
latency to seizure activity in tPA/ mice (P < 0.05,
n = 5) and decreased latency in Nsp/ mice (P < 0.05,
n = 5) relative to WT control mice (n = 7) (Fig. 9A). In
contrast, we found that in ex vivo hippocampal prepara-
tions the genotypic differences were lost or slightly
opposed to the in vivo results (Fig. 9B). The ex vivo
recordings revealed no significant difference between WT
(n = 14) and Nsp/ mice (P = 0.22, n = 11) and a small
decrease in latency to onset observed in the tPA/
(P < 0.05, n = 8) as compared to WT controls. Collec-
tively, these results suggest that the effect of the neuroser-
pin/tPA regulatory circuit on seizure onset/progression is
at the level of the neurovascular unit.
Discussion
The data presented here establish that, in vivo, endogenous
neuroserpin and tPA form a regulatory circuit in the brain
that significantly affects seizure progression. These results
are consistent with previous reports indicating that tPA/
mice are seizure resistant,14,15 that neuronal overexpres-
sion of tPA in mice leads to a lower seizure threshold,16
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Figure 6. PDGFRa is expressed by perivascular astrocytes in the murine brain. Costaining of PDGFRa (green) with (A) glial fibrillary acidic protein,
a marker for astrocytes (GFAP, red) and (B) a-smooth muscle actin, a marker for vascular mural cells (ASMA, red) show expression of PDGFRa in
GFAP-positive perivascular astrocytes (A, arrows), on the parenchymal side of ASMA-positive signal (B, arrowheads). Vessels were visualized using
the endothelial cell marker podocalyxin (Podo, white) and cell nuclei by DAPI (blue). The pictures are representative images from stainings on
sections from three wild-type mice (n = 3) and the stainings have been repeated three independent times per animal. The pictures in (A and B)
show two-dimensional renderings of the three-dimensional reconstruction generated from confocal Z stacks and (A0 and B0) show the xyz
distribution. Scale bars, 10 lm. PDGFRa, platelet-derived growth factor receptor alpha; DAPI, 40,6-diamidino-2-phenylindole, dihydrochloride.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 731
L. Fredriksson et al. Neurovascular Integrity and Seizures
and that mutations in the human neuroserpin gene are
associated with epilepsy.8,9,48–50 We propose that neuroser-
pin and tPA regulate seizure progression primarily
through control of the neurovascular unit and BBB integ-
rity, and not through direct effects of tPA on neuronal
activity. This hypothesis is supported by multiple indepen-
dent experimental results, including the observation that
increasing BBB permeability in seizure-resistant tPA/
mice dramatically enhances the rate of seizure progression,
whereas interventions that maintain BBB integrity delay
seizure propagation in both WT and Nsp/ mice, but not
in tPA/ mice. In addition, the comparison of in vivo
EEG recordings to ex vivo hippocampal electrophysiologi-
cal recordings demonstrates that the phenotypic differ-
ences in seizure progression between WT, tPA/, and
Nsp/ mice are maintained in vivo, but are absent in
ex vivo studies where BBB regulation is no longer neces-
sary for maintenance of the extracellular environment.
Finally, we show that mice with a conditional reduction in
PDGFRa expression in astrocytes have delayed seizure
progression, which is consistent with the hypothesis that
tPA regulates BBB integrity through PDGF-CC induced
activation of PDGFRa signaling in perivascular astro-
cytes.25 The observation that PDGFRa signaling in astro-
cytes plays a role in regulating seizure progression is of
particular interest as earlier reports have suggested that
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Figure 7. Conditional ablation of PDGFRa in perivascular astrocytes improves seizure outcome. (A) Co-immunofluorescent staining of murine
brain sections from astrocyte-specific PDGFRa-deficient mice (Cre+;Rafl/fl) and floxed littermate controls lacking GFAP-driven Cre recombinase
expression (Cre;Rafl/fl) show that perivascular PDGFRa expression (green, arrows) is decreased in the conditional mice (arrowheads). Vessels were
visualized using the endothelial cell marker podocalyxin (white) and cell nuclei by DAPI (blue). The pictures are two-dimensional renderings of the
three-dimensional reconstructions (left panel) and maximum intensity projections (right panels) generated from confocal Z stacks. (B)
Quantification of the amount of PDGFRa-positive staining from five coronal brain sections per animal revealed a significant reduction in PDGFRa
expression in Cre+;Rafl/fl brains (n = 3) as compared to floxed Cre;Rafl/fl controls (n = 3). (C) Convulsive behavior following KA injection was
classified and scored as in Figure 1 in floxed Cre;Rafl/fl (n = 10) and conditional Cre+;Rafl/fl (n = 10) mice. (D) Seizure activity in Cre+;Rawt/wt
(n = 5) mice phenocopied wild-type Cre;Rawt/wt littermate controls (n = 6). (E) Quantification of the amount of PDGFRa-positive staining from
three coronal brain sections per animal (n = 3) in floxed Cre;Rafl/fl and conditional Cre+;Rafl/fl mice as compared to wild-type Cre;Rawt/wt
littermate controls. Data are presented as mean  SEM (B and E) and Kaplan–Meier plots of seizure progression (C and D). Median times (t) are
indicated in the figure. The data are from at least two independent experiments. Statistical significance was determined by Student’s paired t-test
(B and E) and log-rank (Mantel–Cox) test (C and D) and *P < 0.05; **P < 0.01; ns = non significant relative to control. Scale bars, (A) left panel,
10 lm and right panels, 5 lm. PDGFRa, platelet-derived growth factor receptor alpha; GFAP, glial fibrillary acidic protein; DAPI, 40,6-diamidino-2-
phenylindole, dihydrochloride; KA, kainic acid.
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astrocytes play a central role in the pathology of sei-
zures.32,51 Together, our data are consistent with the grow-
ing body of evidence showing that increased BBB
permeability may constitute a significant pathologic factor
in the development of seizures.27,30–32,52 Importantly, our
results identify a specific molecular pathway involving
tPA-mediated PDGFRa signaling in astrocytes that may
regulate this process. We suggest that such a mechanism
may contribute to the development of seizures as a com-
mon sequelae of neuropathological events associated with
significant disruption of the BBB, such as TBI and
stroke.53–56 Indeed, in both ischemic25,57 and hemorrhagic
stroke models58 PDGFRa signaling has been shown to play
a significant role in pathologic BBB dysfunction.
It is well-established that cerebrovascular responses to
neuronal activity are critical for maintaining parenchymal
homeostasis through three closely linked and related
effects: (1) neurovascular coupling, which refers to
increases in cerebral blood flow in response to neuronal
activity; (2) neurobarrier coupling, which refers to
changes in transport or the movement of molecules across
the BBB; and (3) neurometabolic coupling, which refers
to changes in local metabolic factors, such as glucose and
lactate, in response to neuronal activity (reviewed in 59).
Confocal studies of coimmunostainings of neuroserpin
and tPA with various neuronal markers revealed that neu-
roserpin is expressed in specific SST-positive interneu-
rons, whereas tPA was found in VIP-positive neurons.
These data are consistent with the idea of a neuroserpin/
tPA regulatory circuit in the regulation of cerebrovascular
responses as VIP-expressing “vasomotor” interneurons are
reported to induce dilation of local microvessels, whereas
SST-expressing interneurons are known to induce con-
traction.41–43 These data are also in agreement with the
observation that tPA/ mice have a diminished neuro-
vascular coupling response,60 and with recent studies sug-
gesting that tPA may be involved in neurometabolic
coupling.61 We hypothesize that under normal conditions
tPA is released in response to excitatory activity and pro-
motes neurovascular60 and neurobarrier coupling (Fig. 2),
and possibly neurometabolic coupling,61–63 to accommo-
date relatively high firing rates that occur during routine
processing in the neocortex. However, during periods of
aberrantly high firing rates, as occurs during recurring
bouts of ictal activity, neuroserpin is released from inhibi-
tory neurons to reduce coupling (via inhibition of tPA)
which might act to augment GABA mediated feedforward
inhibition that is thought to arise during seizure propaga-
tion.64,65
The role of tPA in the CNS has been controversial.1–
3,66 It has been proposed that tPA directly affects multiple
physiologic processes, such as neuronal development,67
neuronal plasticity,68 axonal regeneration,69,70 as well as
multiple pathologic processes, such as excitotoxicity,71
microglial activation/inflammation,72,73 and BBB dysfunc-
tion.22,25 Multiple potential substrates and receptors for
tPA have also been proposed to mediate these diverse
effects, including plasminogen, NMDA receptors, LRP1,
and PDGF-CC.1–3 However, it is possible that the neuro-
vascular events regulated by tPA and neuroserpin
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Figure 8. Opening of the BBB by mannitol exacerbates seizure outcome. (A) Osmotic opening of the BBB was induced by infusion of high
molarity mannitol through the internal carotid artery in tPA/ mice and visualized by Evans blue (EB) extravasation (arrow). (B) Vascular
permeability was determined 1 h following mannitol treatment by quantitative analysis of EB extravasation in brain extracts. The results show
significantly increased EB levels in tPA/ brain extract following mannitol infusion (n = 6) compared to saline controls (n = 4). (C and D)
Assessment of behavioral seizure manifestations in tPA/ mice after mannitol-induced opening of the BBB (n = 8) revealed significantly faster
onset (C) and generalization (D) compared to saline infused controls (n = 7). Data are presented as mean  SEM (B) and Kaplan–Meier plots (C
and D) from two independent experiments. Median times (t) are indicated in the figure. Statistical significance was determined by (B) unpaired
Student’s t-test and (C and D) log-rank (Mantel-Cox) test. *P < 0.05; ***P < 0.001 significant relative to control. BBB, blood–brain barrier; tPA,
tissue plasminogen activator.
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described here could provide a unifying pathway for
many of the pleotropic effects of tPA. For example, stud-
ies have suggested that a primary role of tPA in the CNS
is direct regulation of neuronal activity through its action
on the NMDA receptor and neuronal calcium signal-
ing.20,21,74 It is conceivable, however, that tPA-induced
changes in BBB permeability could lead to a loss of
precise control of the extracellular environment, which in
turn, could promote dysregulation of neuronal signaling
pathways such as the NMDA pathway. Likewise, tPA has
been suggested to directly promote excitotoxicity.71 In
this latter scenario, it may be that the loss of control of
parenchymal homeostasis due to tPA-mediated changes in
BBB permeability act to promote excitotoxic neuronal
loss by allowing the buildup of parenchymal excitotoxins.
Thus, our data suggest a possible common pathway for
tPA and neuroserpin, permitting modulation of CNS
function through the regulation of the neurovascular unit.
However, it is important to note that although our data
identify a critical neurovascular pathway regulated by
neuroserpin/tPA, this does not rule out their potential
role in the modulation of nonvascular CNS pathways,
and the relative importance of these other potential inter-
actions in different physiologic and pathologic pathways
remains to be determined.
The association of mutations in the human neuroserpin
gene with epilepsy8,9,48–50 has generally been thought to be
due to the neurotoxic effects of neuroserpin inclusion
bodies,11 although loss of regulation of tPA activity has
also been proposed (reviewed in 75). Our results, demon-
strating that Nsp/ mice have a lower threshold for sei-
zures, supports a potential “loss-of-tPA regulation”
mechanism, and thus, suggests a potential pathway for
therapeutic intervention in these patients by blocking tPA-
induced PDGFRa signaling. However, in a recent study by
Tan et al., increased expression of tPA in the murine
brain was found not to influence kindling-induced epile-
ptogenesis, despite a lower threshold for electrically
induced seizures.16 They also showed that the develop-
ment of either early poststroke seizures or acquired epi-
lepsy was not significantly increased following I.V.
administration of thrombolytic tPA in humans.16
Together these studies suggest that tPA does not directly
induce seizures or epilepsy, but instead lowers the thresh-
old of other seizure provoking insults through its effect on
cerebrovascular responses. It should, however, be noted
that in a recent meta-analysis of stroke patients, hemor-
rhagic transformation of ischemic stroke was strongly cor-
related with early poststroke seizures.76 As hemorrhagic
transformation is associated with severe BBB disruption
and is one of the major complications of thrombolytic
tPA therapy, it may be that in this subset of patients
thrombolytic tPA contributes to an increase in early post-
stroke seizures. It will therefore be interesting to find out
whether adjuvant imatinib therapy used with thrombolytic
tPA in ischemic stroke patients leads to a decrease in the
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Figure 9. An intact BBB regulates seizure onset and progression.
Neurophysiological experiments using (A) the in vivo KA seizure model
and interhippocampal EEG recordings or (B) an ex vivo model of
spontaneous synchronous activity induced in hippocampal slices by
exclusion of Mg2+/elevation of K+ concentrations in aCSF. (A)
Monopolar electrodes were positioned into the contralateral
hippocampus and the time to onset of electrographic seizure activity
was determined as described in Methods. The recordings mimic the
clinical scorings presented in Figure 1 and show that in vivo onset of
electrographic seizure activity in wild-type (WT) mice (n = 7) is
intermediate between onset in Nsp/ mice (n = 5, faster) and tPA/
mice (n = 5, slower). (B) Extracellular field potential recordings were
obtained in stratum oriens of the CA3 region in ex vivo brain slices
from WT (n = 14), Nsp/ (n = 11) and tPA/ (n = 8) mice and the
time to the first spontaneous high-frequency burst was recorded as
described in Methods. Data are presented as Kaplan–Meier plots and
median time (t) until electrographic event is indicated in the figure.
The data are from 4 to 10 independent experiments. Statistical
significance was determined by log-rank (Mantel–Cox) test and
*P < 0.05; ns = non significant relative to WT control. BBB, blood–
brain barrier; KA, kainic acid; EEG, electroencephalogram; aCSF,
artificial cerebrospinal fluid; tPA, tissue plasminogen activator.
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incidence of poststroke seizures and epilepsy (ongoing
I-STROKE clinical trial, European Stroke Network).
In conclusion, the data presented here support the
hypothesis that loss of tPA regulation may contribute to
the epilepsy phenotype seen in patients carrying neuroser-
pin mutations. As such, interventions aimed at control-
ling the effects of unregulated tPA activity may provide
some benefit to these patients and possibly to patients
suffering from seizures caused by other disorders. Fur-
thermore, our data indicate that a critical feature control-
ling neuronal activity and seizure development is strict
maintenance of the extracellular environment, as loss of
BBB integrity correlates with loss of neuronal inhibitory
control. Finally, this study suggests that there may be a
common pathway responsible for many of the pleotropic
effects of tPA in the CNS, and that these similar neuro-
vascular signaling events may be common to different
CNS disorders, including ischemic stroke and seizure.
This commonality suggests that other diverse and seem-
ingly unrelated CNS disorders where BBB dysfunction is
involved, including neurodegenerative diseases, may also
be influenced by tPA-mediated PDGFRa signaling.
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